| 000 | 00868 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250517190952.0 | ||
| 264 | 0 | _c20190221 | |
| 008 | 201902s 0 0 eng d | ||
| 022 | _a1365-2044 | ||
| 024 | 7 |
_a10.1111/anae.14037 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBantel, C | |
| 245 | 0 | 0 |
_aBetween evidence and commerce - the case of sufentanil sublingual tablet systems. _h[electronic resource] |
| 260 |
_bAnaesthesia _c02 2018 |
||
| 300 |
_a143-147 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Comment | ||
| 650 | 0 | 4 | _aAnalgesia, Patient-Controlled |
| 650 | 0 | 4 | _aAnalgesics, Opioid |
| 650 | 0 | 4 | _aGabapentin |
| 650 | 0 | 4 | _aSufentanil |
| 650 | 0 | 4 | _aTablets |
| 700 | 1 | _aLaycock, H C | |
| 773 | 0 |
_tAnaesthesia _gvol. 73 _gno. 2 _gp. 143-147 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/anae.14037 _zAvailable from publisher's website |
| 999 |
_c27868035 _d27868035 |
||